Xiamen Amoytop Biotech Co., Ltd.

688278

CNE100003RT3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
54.65 ^CNY	+0.94%		+0.09%	+4.39%

Apr. 22	Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 18	China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6%	MT

Huihe Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shanghai Prosperico Ventures Co., Ltd., Shenzhen Capital Group Co., Ltd., Jolmo Investment Management Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Hangzhou Tailong Venture Capital Partnership Enterprise (L.P.)

May 14, 2023

Huihe Biotechnology (Shanghai) Co., Ltd. announced that it has raised CNY 100 million in funding led by new investors Shanghai Prosperico Ventures Co., Ltd., Jolmo Investment Management Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Hangzhou Tailong Venture Capital Partnership Enterprise (L.P.) and Shenzhen Capital Group Co., Ltd. on May 15, 2023.

Latest news about Xiamen Amoytop Biotech Co., Ltd.

Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6%	Mar. 18	MT
Xiamen Amoytop Biotech Gets Nod to Market Hepatitis Drug; Shares Up 4%	Mar. 18	MT
Amoytop Biotech's 2023 Profit Jumps 93%	Feb. 26	MT
Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
'Hawkish' China military squeeze on Taiwan likely after election	Jan. 03	RE
Taiwan not seeing signs of large-scale Chinese military activity pre-election	Dec. 25	RE
Taiwan to 'handle' spate of Chinese balloons based on threat level	Dec. 20	RE
Taiwan reports more suspected Chinese weather balloons crossing Taiwan Strait	Dec. 17	RE
Xiamen Amoytop Biotech Co., Ltd.(SHSE:688278) added to Shanghai Stock Exchange Health Care Sector Index	Dec. 11	CI
Amoytop Biotech Signs Exclusive License Deal for Liver Disease Drug With Alphamab Unit	Dec. 07	MT
Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-19	CI
Taiwan raises concerns about situation 'getting out of hand' with China drills	23-09-22	RE
Xiamen Amoytop Biotech Co., Ltd.(XSSC:688278) added to S&P Global BMI Index	23-09-18	CI
Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Amoytop Biotech Signs Exclusive Commercialization Deal With Fosun Unit	23-06-01	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-05-15	MT
Top Premarket Gainers	23-05-15	MT
Aligos Therapeutics to Collaborate with Xiamen Amoytop Biotech on Liver Disease Treatments; Aligos Shares Jump	23-05-15	MT
Huihe Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shanghai Prosperico Ventures Co., Ltd., Shenzhen Capital Group Co., Ltd., Jolmo Investment Management Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Hangzhou Tailong Venture Capital Partnership Enterprise (L.P.)	23-05-14	CI
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases	23-05-12	CI
Amoytop Biotech to Co-Develop Hepatitis Treatment With US-Based Aligos	23-05-12	MT
Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Amoytop Biotech Gets Regulatory Nod for Anti-COVID-19 Spray Trial	23-01-10	MT

Chart Xiamen Amoytop Biotech Co., Ltd.

Duration

Period

More charts

Company Profile

XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Xiamen Amoytop Biotech Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

54.65 CNY

Average target price

86.1 CNY

Spread / Average Target

+57.55%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
XIAMEN AMOYTOP BIOTECH CO., LTD.	+4.39%	3.07B
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B
INNOVENT BIOLOGICS, INC.	-17.66%	7.32B

Biopharmaceuticals

Xiamen Amoytop Biotech Co., Ltd.

Equities

688278

CNE100003RT3

Pharmaceuticals

Latest news about Xiamen Amoytop Biotech Co., Ltd.

Chart Xiamen Amoytop Biotech Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Xiamen Amoytop Biotech Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals